Weight-loss drug forecasts jump to $150 billion as supply grows

As millions seek access to weight-loss drugs from Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N) increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s.